VitaNova Life Sciences (VNOV) Receivables - Other (2019 - 2026)

VitaNova Life Sciences has disclosed Receivables - Other across 4 years of filings, most recently posting -$172310.0 for Q1 2026.

• Receivables - Other for Q1 2026 came in at -$172310.0, changed N/A year-over-year; the trailing twelve-month figure through Apr 2026 was -$158802.0 (up 47.43% YoY), and the FY2026 annual result was -$158802.0, up 47.43% from the prior year.
• Receivables - Other for Q1 2026 stood at -$172310.0, down from $13508.0 in the prior quarter.
• Across five years, Receivables - Other topped out at $460870.0 in Q2 2024 and bottomed at -$512980.0 in Q2 2025.
• Average Receivables - Other over 3 years is $22285.7, with a median of $13508.0 recorded in 2025.
• On a YoY basis, Receivables - Other climbed as much as 108.02% in 2025 and fell as far as 211.31% in 2025.
• Year by year, Receivables - Other stood at -$168480.0 in 2024, then soared by 108.02% to $13508.0 in 2025, then sank by 1375.61% to -$172310.0 in 2026.
• The last three Receivables - Other figures came in at -$172310.0 (Q1 2026), $13508.0 (Q4 2025), and -$512980.0 (Q2 2025), per Business Quant data.